The Ventilator Associated Pneumonia (VAP) drugs in development market research report provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Ventilator Associated Pneumonia (VAP). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued products.
GlobalData tracks 33 drugs in development for Ventilator Associated Pneumonia (VAP) by 30 companies/universities/institutes. The top development phase for Ventilator Associated Pneumonia (VAP) is discovery with seven drugs in that stage. The Ventilator Associated Pneumonia (VAP) pipeline has 33 drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Ventilator Associated Pneumonia (VAP) pipeline products market are: Helperby Therapeutics Group, Sumitomo Pharma and SciClone Pharmaceuticals.
The key targets in the Ventilator Associated Pneumonia (VAP) pipeline products market include Beta Lactamase, Penicillin Binding Protein, and Bacterial Cell Membrane.
The key mechanisms of action in the Ventilator Associated Pneumonia (VAP) pipeline product include Beta Lactamase Inhibitor with nine drugs in Pre-Registration. The Ventilator Associated Pneumonia (VAP) pipeline products include four routes of administration with the top ROA being Intravenous and eight key molecule types in the Ventilator Associated Pneumonia (VAP) pipeline products market including Small Molecule, and Biologic.
Ventilator Associated Pneumonia (VAP) overview
Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in the blood).
For a complete picture of Ventilator Associated Pneumonia (VAP)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
